LuciLeter (letermovir 240 mg tablets) is an antiviral medication indicated for the prevention of cytomegalovirus (CMV) infection in specific transplant populations. To ensure its optimal effectiveness and minimize potential risks, it is essential to follow proper administration and monitoring practices. Below are professionally outlined recommendations for patients and caregivers.
1. How to Take LuciLeter
- Dosage Form: LuciLeter is available as a 240 mg oral tablet.
- Administration Frequency: The medication is taken once daily.
- Swallow Whole: Do not chew, split, or crush the tablet. Swallow it whole with a glass of water.
- With or Without Food: LuciLeter may be taken with or without meals, providing flexibility based on patient preference and tolerance.
- Missed Dose Protocol:
- If a dose is missed, it should be taken as soon as remembered.
- If the time for the next scheduled dose is near, skip the missed dose and continue with the regular schedule.
- Do not take two doses to compensate for a missed one.
2. Recommended Dosage
For Adult and Pediatric Patients (≥12 years and ≥30 kg):
- Standard Dose: 480 mg once daily (two 240 mg tablets).
- When Co‑administered with Cyclosporine: Reduce to 240 mg once daily (one 240 mg tablet).
- Treatment Duration:
- HSCT (Hematopoietic Stem Cell Transplant): Initiate between Day 0 and Day 28 post‑transplant and continue through Day 100. In high‑risk patients, continue up to Day 200.
- Kidney Transplant: Initiate between Day 0 and Day 7 post‑transplant and continue through Day 200.
For Pediatric Patients (<12 years or <30 kg):
- Dose is based on body weight.
- Refer to standardized dosing tables as provided in clinical guidelines.
- Close monitoring and adjustment are required when switching between oral and IV (intravenous) formulations or when co‑administered with cyclosporine.
3. Monitoring and Follow‑Up
- CMV Monitoring: After discontinuing LuciLeter, continued surveillance for CMV reactivation is recommended especially in HSCT recipients.
- Drug Interaction Monitoring: LuciLeter interacts with certain drugs, especially cyclosporine. Adjust doses accordingly and under clinical supervision.
- Laboratory Tests:
- Periodic liver function tests, renal panels, and complete blood counts may be required.
- Monitor for adverse reactions or breakthrough infections.
4. Storage and Handling
- Store at room temperature (typically 20–25 °C or 68–77 °F).
- Keep in a dry place, protected from light and moisture.
- Keep out of reach of children and store in original packaging until use.
5. When to Call Your Doctor
Contact your healthcare provider if you notice:
- Signs of an allergic reaction: rash, swelling, or trouble breathing.
- Fever or flu-like symptoms.
- Any new or worsening side effects.
- Difficulty taking the medication or sticking to your schedule.
Summary of Best Practices
| Category | Guidance |
|---|---|
| When to Take | Once daily, same time every day |
| How to Take | Oral, with or without food |
| Tablet Rules | Do not crush, chew, or split |
| Missed Dose | Skip if close to next dose; never double the dose |
| Drug Interactions | Adjust dose when taking with cyclosporine |
| Monitoring | Regular tests for CMV, liver, and kidney function |
| Children’s Doses | Use weight-based doses and specialist oversight |
Adhering to these usage guidelines will help maximize LuciLeter’s protective benefits and reduce the risk of CMV‑related complications. Patients should always follow their physician’s specific instructions, and healthcare providers should individualize therapy based on transplant type, concurrent medications, and patient risk factors.
